CN101906464B - 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法 - Google Patents

产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法 Download PDF

Info

Publication number
CN101906464B
CN101906464B CN2010102215832A CN201010221583A CN101906464B CN 101906464 B CN101906464 B CN 101906464B CN 2010102215832 A CN2010102215832 A CN 2010102215832A CN 201010221583 A CN201010221583 A CN 201010221583A CN 101906464 B CN101906464 B CN 101906464B
Authority
CN
China
Prior art keywords
protein
cell
sequence
peptide
subtilisin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010102215832A
Other languages
English (en)
Chinese (zh)
Other versions
CN101906464A (zh
Inventor
D·A·埃斯特尔
F·A·哈丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor International Inc filed Critical Genencor International Inc
Publication of CN101906464A publication Critical patent/CN101906464A/zh
Application granted granted Critical
Publication of CN101906464B publication Critical patent/CN101906464B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
CN2010102215832A 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法 Expired - Fee Related CN101906464B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/500,135 2000-02-08
US09/500,135 US6838269B1 (en) 1998-04-15 2000-02-08 Proteins producing an altered immunogenic response and methods of making and using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN01804669A Division CN1418253A (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法

Publications (2)

Publication Number Publication Date
CN101906464A CN101906464A (zh) 2010-12-08
CN101906464B true CN101906464B (zh) 2013-03-27

Family

ID=23988185

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010102215832A Expired - Fee Related CN101906464B (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法
CN01804669A Pending CN1418253A (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法
CNA2005100836207A Pending CN1721442A (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN01804669A Pending CN1418253A (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法
CNA2005100836207A Pending CN1721442A (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法

Country Status (12)

Country Link
US (1) US6838269B1 (https=)
EP (1) EP1254240B1 (https=)
JP (1) JP5112587B2 (https=)
KR (1) KR20020073582A (https=)
CN (3) CN101906464B (https=)
AR (1) AR027358A1 (https=)
AT (1) ATE355377T1 (https=)
AU (1) AU3651201A (https=)
CA (1) CA2399019A1 (https=)
DE (1) DE60126915T2 (https=)
DK (1) DK1254240T3 (https=)
WO (1) WO2001059130A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967080B1 (en) * 1990-12-05 2005-11-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CA2249648A1 (en) * 1998-11-04 2000-05-04 Nabil G. Seidah Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
CN1491232A (zh) * 2001-02-06 2004-04-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰肥胖蛋白
US20050054843A1 (en) * 2001-12-31 2005-03-10 Estell David A Proteases producing an altered immunological response and methods of making and using the same
EP2287320B1 (en) * 2002-01-16 2014-10-01 Danisco US Inc. Multiply-substituted protease variants
AU2003213580A1 (en) * 2002-02-26 2003-09-09 Genencor International, Inc. Subtilisin carlsberg proteins with reduced immunogenicity
EP1520017A2 (en) * 2002-06-26 2005-04-06 Novozymes A/S Subtilases and subtilase variants having altered immunogenicity
EP2500423B1 (en) * 2003-02-26 2015-06-17 Danisco US Inc. Amylases producing an altered immunogenic response and methods of making and using the same
WO2004078960A1 (en) * 2003-02-26 2004-09-16 Genencor International, Inc. Amylases producing an altered immunogenic response and methods of making and using the same
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
EP1877087B1 (en) * 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
US10550381B2 (en) 2014-07-04 2020-02-04 Novozymes A/S Variant proteases and amylases having enhanced storage stability
EP3739029A1 (en) 2014-07-04 2020-11-18 Novozymes A/S Subtilase variants and polynucleotides encoding same
CN109715792A (zh) * 2016-06-03 2019-05-03 诺维信公司 枯草杆菌酶变体和对其进行编码的多核苷酸
WO2026024921A1 (en) * 2024-07-25 2026-01-29 The Procter & Gamble Company Detergent composition comprising a subtilisin variant and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010755A1 (en) * 1990-12-05 1992-06-25 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO1999053038A2 (en) * 1998-04-15 1999-10-21 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430453B1 (fr) 1978-07-04 1986-04-18 Novo Industri As Produit proteasique a pouvoir allergisant reduit
US5763257A (en) * 1984-05-29 1998-06-09 Genencor International, Inc. Modified subtilisins having amino acid alterations
US5593877A (en) * 1993-03-11 1997-01-14 The Rockefeller University Nucleic acid and recombinant production of vespid venom hyaluronidase
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
WO1996016177A1 (en) 1994-11-24 1996-05-30 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
US5951980A (en) * 1995-01-06 1999-09-14 Leuven Research & Development Vzw Identification, production and use of new staphylokinase derivatives with reduced immunogenicity
US5837517A (en) * 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
ATE429490T1 (de) 1995-05-05 2009-05-15 Novozymes As Protease-varianten und verbindungen
CN1273589C (zh) 1996-02-15 2006-09-06 诺沃奇梅兹有限公司 多肽缀合
EP0932667B1 (en) 1996-11-04 2008-10-01 Novozymes A/S Subtilase variants and compositions
WO1999006061A1 (en) 1997-07-29 1999-02-11 The Administrators Of The Tulane Educational Fund Prediction, detection, and design of t cell epitopes
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
CA2238660A1 (en) 1998-05-22 1999-11-22 Janet Chantler Gene sequences of rubella virus associated with attenuation
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010755A1 (en) * 1990-12-05 1992-06-25 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO1999053038A2 (en) * 1998-04-15 1999-10-21 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins

Also Published As

Publication number Publication date
JP5112587B2 (ja) 2013-01-09
US6838269B1 (en) 2005-01-04
WO2001059130A3 (en) 2002-03-07
EP1254240B1 (en) 2007-02-28
AR027358A1 (es) 2003-03-26
CA2399019A1 (en) 2001-08-16
CN1721442A (zh) 2006-01-18
DE60126915D1 (de) 2007-04-12
ATE355377T1 (de) 2006-03-15
CN101906464A (zh) 2010-12-08
EP1254240A2 (en) 2002-11-06
AU3651201A (en) 2001-08-20
WO2001059130A2 (en) 2001-08-16
KR20020073582A (ko) 2002-09-27
CN1418253A (zh) 2003-05-14
JP2004500088A (ja) 2004-01-08
DE60126915T2 (de) 2007-11-15
DK1254240T3 (da) 2007-07-02

Similar Documents

Publication Publication Date Title
CN101906464B (zh) 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法
US6596525B1 (en) Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6642011B2 (en) Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6936249B1 (en) Proteins producing an altered immunogenic response and methods of making and using the same
JP5126761B2 (ja) 変化した免疫反応をもたらすタンパク質及びその作成または使用方法
MXPA00009923A (en) Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
HK1070247A1 (en) Method of determining the immunogenicity of proteins producing an altered immunogenic response
HK1070247B (en) Method of determining the immunogenicity of proteins producing an altered immunogenic response
MXPA00009916A (en) Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: Claims1

Correct: T- cell

False: T, cell

Number: 13

Volume: 29

CI03 Correction of invention patent

Correction item: Claims1

Correct: T- cell

False: T, cell

Number: 13

Page: Description

Volume: 29

ERR Gazette correction

Free format text: CORRECT: CLAIM OF RIGHT 1; FROM: T, CELL TO: T-CELL

RECT Rectification
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130327

Termination date: 20160122

EXPY Termination of patent right or utility model